Heartflow, an AI-enabled cardiac diagnostic software company, made a strong Nasdaq debut with a $2.27 billion valuation, exceeding initial projections of $1.3-1.5 billion. Founded in 2007, the company offers pay-per-use visualization technology for coronary artery disease, eliminating the need for invasive procedures. Recent quarterly revenues increased by 40% year-over-year to $43.4 million. Backed by Bain Capital, Hayfin, and Wellington, Heartflow plans to use IPO proceeds to repay debt, expand marketing, and invest in software development. This successful debut signals renewed interest in healthcare IPOs and positions Heartflow for continued growth in AI-driven cardiac diagnostics.